PEA bridging study terminated early
The ICA regret to announce the early termination of the PEA bridging study, a randomised, placebo-controlled, double-blind clinical trial to determine the efficacy of riociguat on pre- and post-operative pulmonary haemodynamic parameters in patients with severe operable CTEPH. The reasons for this difficult decision were slow enrolment and the additional limitations on clinical research imposed by the COVID-19 pandemic. At the time of termination, 11 patients had completed study treatment.
Analysis of the collected data is ongoing to determine whether any insights can be gathered. Despite this setback, the ICA remain committed to their main goal of advancing the management of CTEPH patients to improve clinical outcomes.